Citigroup’s KalVista Pharmaceuticals KALV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$3.38M Buy
299,194
+150,967
+102% +$1.71M ﹤0.01% 1690
2025
Q1
$1.71M Sell
148,227
-179,069
-55% -$2.07M ﹤0.01% 2198
2024
Q4
$2.77M Buy
327,296
+21,792
+7% +$185K ﹤0.01% 1891
2024
Q3
$3.54M Buy
305,504
+19,440
+7% +$225K ﹤0.01% 1591
2024
Q2
$3.37M Buy
286,064
+3,181
+1% +$37.5K ﹤0.01% 1407
2024
Q1
$3.35M Buy
282,883
+974
+0.3% +$11.6K ﹤0.01% 1486
2023
Q4
$3.45M Buy
281,909
+4,991
+2% +$61.1K ﹤0.01% 1315
2023
Q3
$2.67M Sell
276,918
-22,890
-8% -$220K ﹤0.01% 1325
2023
Q2
$2.7M Buy
299,808
+22,902
+8% +$206K ﹤0.01% 1470
2023
Q1
$2.18M Sell
276,906
-165
-0.1% -$1.3K ﹤0.01% 1488
2022
Q4
$1.87M Buy
277,071
+276,402
+41,316% +$1.87M ﹤0.01% 1566
2022
Q3
$10K Sell
669
-1,478
-69% -$22.1K ﹤0.01% 4252
2022
Q2
$21K Sell
2,147
-6,290
-75% -$61.5K ﹤0.01% 4276
2022
Q1
$124K Sell
8,437
-45,690
-84% -$672K ﹤0.01% 3635
2021
Q4
$716K Buy
54,127
+25,139
+87% +$333K ﹤0.01% 2833
2021
Q3
$506K Sell
28,988
-68,829
-70% -$1.2M ﹤0.01% 2875
2021
Q2
$2.34M Buy
97,817
+73,132
+296% +$1.75M ﹤0.01% 1987
2021
Q1
$634K Buy
24,685
+21,109
+590% +$542K ﹤0.01% 2676
2020
Q4
$68K Buy
3,576
+2,658
+290% +$50.5K ﹤0.01% 3917
2020
Q3
$12K Sell
918
-1,362
-60% -$17.8K ﹤0.01% 4212
2020
Q2
$28K Sell
2,280
-1,607
-41% -$19.7K ﹤0.01% 4040
2020
Q1
$30K Buy
3,887
+1,357
+54% +$10.5K ﹤0.01% 4142
2019
Q4
$45K Buy
2,530
+1,951
+337% +$34.7K ﹤0.01% 4032
2019
Q3
$6K Sell
579
-2,681
-82% -$27.8K ﹤0.01% 4732
2019
Q2
$72K Sell
3,260
-8,978
-73% -$198K ﹤0.01% 3837
2019
Q1
$350K Buy
+12,238
New +$350K ﹤0.01% 2745
2016
Q2
Sell
-725
Closed -$7K 5090
2016
Q1
$7K Buy
725
+461
+175% +$4.45K ﹤0.01% 4868
2015
Q4
$13K Buy
264
+260
+6,500% +$12.8K ﹤0.01% 4676
2015
Q3
$0 Sell
4
-7
-64% ﹤0.01% 5368
2015
Q2
$1K Buy
+11
New +$1K ﹤0.01% 5337